Zenas BioPharma, Inc. (ZBIO) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Zenas BioPharma, Inc. stock $15.73, price $27.93, that is 43.7% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Zenas BioPharma, Inc.
ZBIO · USFar too expensive (fair value 44% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
26‑month range $6.43 – $43.17 · fair‑value band $11.79 – $19.66 · the $27.93 price screens above the $15.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Zenas BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Show moreShow less
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Stock analysis
Zenas BioPharma, Inc. (ZBIO) currently trades at $27.93, while our estimate is $15.73, 44% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $11.79 (bear) to $19.66 (bull), the price of $27.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Zenas BioPharma, Inc. reported revenue of $10.0M in FY2025 versus $0 in FY2022. Reported net income was −$378M in FY2025.
Key figures
Market cap $1.9B Small · EPS (TTM) $−10.08 · Return on equity −265% · Return on assets (EBIT) −64.0% (4-year average) · Operating margin −759% · Revenue (TTM) $11.0M · Free cash flow −$172M · Net cash $30.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and 84% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −44%, ZBIO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $1.0M, on May 18, 2026.
- BuyLeon O Moulder JrChief Executive Officer, Director5× since Jan 7, 2026: 331,000 shares, avg. $17.41$5.8MMay 18, 2026
- BuyHongbo LuDirector3× since Feb 11, 2026: 104,753 shares, avg. $20.57$2.2MMar 31, 2026
- BuyTomas KiselakDirector150,000 shares at $20.00$3.0MMar 31, 2026
- BuyPatricia L AllenDirector19,860 shares at $25.16$499,746Feb 13, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Compare Zenas BioPharma, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ZBIO |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ZBIO |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs ZBIO |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ZBIO |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ZBIO |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ZBIO |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs ZBIO |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ZBIO |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs ZBIO |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ZBIO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Zenas BioPharma, Inc. (ZBIO) overvalued or undervalued?
What is the fair value of ZBIO?
What is the quality score of ZBIO?
What is the price target for Zenas BioPharma, Inc. (ZBIO)?
What is the Zenas BioPharma, Inc. stock forecast for 2026?
What is the revenue of Zenas BioPharma, Inc. (ZBIO)?
What is the intrinsic value of Zenas BioPharma, Inc. (ZBIO)?
Is Zenas BioPharma, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ZBIO?
How much is Zenas BioPharma, Inc. worth?
What do the bullish and bearish scenarios say about ZBIO?
How solid is the balance sheet of Zenas BioPharma, Inc. (ZBIO)?
How far is ZBIO from its 52-week high?
Which stocks are comparable to Zenas BioPharma, Inc.?
Is Zenas BioPharma, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Zenas BioPharma, Inc. (ZBIO)?
What should I pay attention to with Zenas BioPharma, Inc. right now?
Key figures of Zenas BioPharma, Inc.
How large is the market capitalisation of Zenas BioPharma, Inc. (ZBIO)?
What are the earnings per share of Zenas BioPharma, Inc. (ZBIO)?
What is the return on equity of Zenas BioPharma, Inc. (ZBIO)?
What is the EBIT return on assets of Zenas BioPharma, Inc. (ZBIO)?
What is the operating margin of Zenas BioPharma, Inc. (ZBIO)?
How much free cash flow does Zenas BioPharma, Inc. (ZBIO) generate?
How much net cash does Zenas BioPharma, Inc. (ZBIO) hold?
Watch Zenas BioPharma, Inc. in the live analysis
One click puts Zenas BioPharma, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.